Market Cap : 1.77 B | Enterprise Value : 1.78 B | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Myovant Sciences's quick ratio for the quarter that ended in Jun. 2022 was 1.79.
Myovant Sciences has a quick ratio of 1.79. It generally indicates good short-term financial strength.
The historical rank and industry rank for Myovant Sciences's Quick Ratio or its related term are showing as below:
During the past 7 years, Myovant Sciences's highest Quick Ratio was 30.53. The lowest was 0.02. And the median was 2.65.
MYOV's Quick Ratio is ranked worse thanThe historical data trend for Myovant Sciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Myovant Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Myovant Sciences's Quick Ratio for the fiscal year that ended in Mar. 2022 is calculated as
Quick Ratio (A: Mar. 2022 ) | = | (Total Current Assets | - | Total Inventories) | / | Total Current Liabilities |
= | (488.145 | - | 7.584) | / | 250.33 | |
= | 1.92 |
Myovant Sciences's Quick Ratio for the quarter that ended in Jun. 2022 is calculated as
Quick Ratio (Q: Jun. 2022 ) | = | (Total Current Assets | - | Total Inventories) | / | Total Current Liabilities |
= | (426.829 | - | 21.222) | / | 226.241 | |
= | 1.79 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Myovant Sciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Valente Nancy | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Mehra Uneek | officer: Principal Financial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Merendino Lauren | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Marek David C | director, officer: Principal Executive Officer | C/O WEBMD HEALTH CORP. 111 EIGHTH AVENUE NEW YORK NY 10011 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 7-1, NIHONBASHI 2-CHOME CHUO-KU TOKYO M0 103-6020 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Lo Andrew | 10 percent owner | C/O ALPHASIMPLEX GROUP, LLC ONE CAMBRIDGE CENTER, 9TH FLOOR CAMBRIDGE MA 02142 |
Viking Global Equities Master Ltd. | 10 percent owner | 55 RAILROAD AVENUE GREENWICH CT 06830 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
From GuruFocus
Other Sources
By Zacks 2021-07-01
By Zacks 2021-09-10
By Fool 2020-12-28
By Zacks 2020-12-29
By Seekingalpha 2021-02-11
By Fool 2021-07-28
By Zacks 2021-10-26
By Seekingalpha 2021-06-02
By Zacks 2021-05-27
By Zacks 2021-05-11
By Zacks 2021-10-29
By Seekingalpha 2021-10-26
By Seekingalpha 2021-01-19
By Zacks 2020-12-16